Ann: Phase II TACTI-002 trial recruitment successfully completed, page-20

Interesting kernels of information have emerged.

This, from the outlook for the remainder of 2021 and 2022
”Potential new studies (financed)”.

Sadly, not one of the “analysts” on the Q&A drilled down on that bullet point. Nor, did they ask how AIPAC phase3 would be financed. Maybe they keep the important questions to themselves for “off air” Q&A.

Anyway. Another interesting snippet from the recent Q&A. Marc mentioned that Efti wouldn’t work administered at the same time with lag3 antibodies(such as Relatlimab) but it might work in an alternating treatment regime.
And, Marc has recently mentioned that the Efti mode of action may be at its most effective in conjunction with checkpoint inhibitors and chemo combos.

In the light of the outstanding results Efti is pulling combined with no side effects(except injection site inflammation) in the current trials. The above information only leads to the conclusion that Efti is likely to open the door to a big advance in cancer treatment efficacy across a range of cutting edge chemo/immuno combinations.

Insight-003 should give us another peak into how broad this potential might be next year.

(DYOR)